title: [Transdermal System-Buprenorphine and Fentanyl].
abstract: Pain management with transdermal opioids is a useful choice in light of longer duration of action, being not affected by oral intake, and with less adverse effect Recently, transdermal fentanyl and buprenorphine are permitted for musculoskeletal non-malignant pain as a new indication. In Japan, one of the world's fastest aging society, it is a welcome step in terms of pain control. However, proper monitoring and management are required. This article reviews the pharmacology, therapeutic efficacy and adverse effect of buprenorphine transdermal patch, and clinical application in cancer pain management of fentanyl patch.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sakurai
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005283:Fentanyl / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010146:Pain / Q000188:drug therapy; D059408:Pain Management; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine; D005283:Fentanyl